Long-term experience, a multidisciplinary team, as well as the passion for science and state of the art research, leading to overall client satisfaction make IASON consulting the number one choice when it comes to pathological peer reviews.
IASON consulting has successfully provided consulting services throughout the health science sector since 2004 and we have thorough experience throughout the entire sector of the health science industry, including drug and device development.
The IASON consulting team consists of experienced and engaged pathologists, toxicologists, biologists, and veterinarians, contributing their broad know-how and experience to make your very project a success.
Passion and our determination to provide the best possible service to our clients is our motor within this very demanding industry. Even with our extensive experience, no two projects are alike and we are looking forward to every challenge on today’s market.
Overall client satisfaction is a number one priority for every IASON consultant. No matter if long-term or short notice projects and consultations, every single request is handled and worked out according to our high-quality standards and integrity.
Pathology Peer Review by IASON consulting for nonclinical toxicology studies supports you in verifying the accurate diagnosis and recording of all pathology findings and to support the integrated interpretation of all pathology information within the context of the entire study to identify and characterize treatment-related findings.
Pathology peer review usually is appropriate for GLP toxicity, carcinogenicity studies, and biomarker qualification studies and may add value for mechanistic and investigative studies with pathology endpoints and exploratory (non-GLP) toxicity studies that guide compound development decisions and dose selection.
Pathology peer review is recommended prior to study completion when important risk assessment or business decisions will be based on nonclinical studies.
For example, the U.S. Environmental Protection Agency (EPA) requires peer review of pathology data and confirmation of changes by a Pathology Working Group for all submissions requesting reconsideration of carcinogenicity decisions for chemicals based on changes in the pathology diagnoses (EPA 1994).
Sponsors and regulatory agencies generally acknowledge that pathology peer review can increase confidence in the pathology data and pathology interpretations.
Reduce your time and costs of gaining regulatory approval for your studies and allow a faster return on your investments.